Raymond James Financial
BLRX

Raymond James Financial’s BioLineRX BLRX Stock Holding History

Raymond James Financial’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72
Closed -$329 – 5182
2025
Q2 		$329 Buy
+72
New +$266 ﹤0.01% 6728

Other funds holding BLRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial's BLRX Position: Q3 2025 in Review

Raymond James Financial sold out of BioLineRX (BLRX) in Q3 2025, closing a stake of 72 shares — an estimated $329 sold.

Raymond James Financial first reported a position in BLRX in Q2 2025 and held it in 1 quarter. The position peaked at $329 in Q2 2025. 14 funds tracked by Wall St. Rank hold BLRX as of Q3 2025.

  • Raymond James Financial reported no remaining BioLineRX position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 72 BioLineRX shares in Q3 2025, an estimated $329.
  • Raymond James Financial first reported a position in BioLineRX in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's BioLineRX position peaked at $329 in Q2 2025.
  • 14 funds tracked by Wall St. Rank held BioLineRX as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.